These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34517157)

  • 1. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
    Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
    Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
    Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
    J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
    Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
    Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
    Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
    Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
    Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
    Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas].
    Liu N; Niu Y; Wang SL; Yu Q; Zhang RJ; Liu TJ
    Zhonghua Yi Xue Za Zhi; 2010 May; 90(20):1403-7. PubMed ID: 20646630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial Differences in the Association Between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival.
    Byun JS; Singhal SK; Park S; Yi DI; Yan T; Caban A; Jones A; Mukhopadhyay P; Gil SM; Hewitt SM; Newman L; Davis MB; Jenkins BD; Sepulveda JL; De Siervi A; Nápoles AM; Vohra NA; Gardner K
    Clin Cancer Res; 2020 Apr; 26(8):1905-1914. PubMed ID: 31911546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy.
    Tanaka K; Tokunaga E; Yamashita N; Sagara Y; Ohi Y; Taguchi K; Ohno S; Okano S; Oda Y; Maehara Y
    Breast Cancer; 2017 May; 24(3):384-392. PubMed ID: 27473079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
    Endo Y; Toyama T; Takahashi S; Yoshimoto N; Iwasa M; Asano T; Fujii Y; Yamashita H
    Endocr Relat Cancer; 2013 Feb; 20(1):91-102. PubMed ID: 23183268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
    J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer.
    Khokher S; Qureshi MU; Mahmood S; Nagi AH
    Asian Pac J Cancer Prev; 2013; 14(5):3223-8. PubMed ID: 23803108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
    Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
    Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
    Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
    Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
    Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
    J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
    Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.